Larazotide
Octapeptide tight-junction regulator. Antagonizes zonulin to restore intestinal epithelial barrier integrity.
This compound sits in research-grey territory. The caveats below carry more weight than for FDA-approved entries — read them.
9 Meters Biopharma's lead candidate (CEDLARA Phase 3 in celiac). Reduces tight-junction permeability rather than directly modulating immune cells. Phase 3 results were mixed in 2022. Still positioned as an adjunct for refractory celiac and explored for long-COVID gut symptoms.
Not approved. Phase 3 results were not unambiguously positive. Self-experimentation outside trial protocols carries unknown long-term risk for chronic GI conditions.
Per-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.
- CLimited evidence
Larazotide — primary mechanism: octapeptide tight-junction regulator. antagonizes zonulin to restore intestinal epithelial barrier integrity.
2 supporting referencesVerified 5d ago
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
Pre-filled with this compound's published dose range: 0.5 mg · before meals, oral
Calculator is a discussion tool. Verify reconstitution + dosing with a qualified provider. Stack is not a prescription source. Use sterile technique and inspect every vial.
Investigational — phase 3 celiac results mixed 2022